At its founding, Milestone assembled a panel of leading pharmaceutical R&D executives with an average of 30 years’ experience in drug development. Our executive team proposed small molecule projects based on clinically-proven science, which became the foundation of Milestone’s drug development programs.

The Company employs a lean and cost-efficient model which has the effect of minimizing overhead and focusing spending on the programs. We have assembled a core seasoned leadership team with expertise in cardiovascular clinical drug development, regulatory affairs and quality assurance, chemistry and manufacturing, and commercial preparedness, which is guided by world-class key opinion leaders and scientific advisors.